AndrewWPippasMD

Oncology • Columbus, GA

Medical Director and Director of Clinical Oncology at Georgia Center for Oncology Research and Education

Join to view full profile

Are you Dr. Pippas?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

Connect with colleagues in the same hospital or clinic
You already have 87 invites waiting!
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

Claim this profile

Not you? Find your profile

Office
1831 5th Avenue
Columbus, GA 31904
Phone+1 706-320-8780

Fax+1 706-320-8721
Is this information wrong?

Summary

Dr. Andrew Pippas, MD is an oncologist in Columbus, Georgia. He is currently licensed to practice medicine in Georgia, Florida, and North Carolina. He is affiliated with Piedmont Columbus Regional - Midtown West, Piedmont Columbus Regional Midtown, and St. Francis Hospital.

Education & Training

Duke University HospitalFellowship, Hematology and Medical Oncology, 1989 - 1992
Duke University HospitalResidency, Internal Medicine, 1986 - 1989
University of Utah School of MedicineClass of 1986

Certifications & Licensure

GA State Medical License 2003 - 2025
FL State Medical License 1995 - 2004
NC State Medical License 1993 - 1999
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Clinical Trials

Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Start of enrollment: 2008 Aug 08
Active, not recruiting
Phase 3
Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy Start of enrollment: 2008 Nov 10
Active, not recruiting
Phase 3
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer Start of enrollment: 2011 Jan 15
Active, not recruiting
Phase 3
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer Start of enrollment: 2011 Jan 06
Active, not recruiting
Phase 3
S0820, Adenoma and Second Primary Prevention Trial Start of enrollment: 2013 Mar 01
Recruiting
Phase 3
S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer Start of enrollment: 2012 Feb 01
Completed
Phase 2
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery Start of enrollment: 2012 Aug 08
Active, not recruiting
Phase 3
S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer Start of enrollment: 2013 Mar 01
Active, not recruiting
Phase 3
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors Start of enrollment: 2013 Jun 21
Active, not recruiting
Phase 2
Expanded Treatment Protocol With LDK378 in ALK(+) NSCLC
No longer available
Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis Start of enrollment: 2014 Mar 21
Active, not recruiting
Phase 3
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches Start of enrollment: 2014 Nov 01
Completed
Phase 2
Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Sep 01
Completed
Phase 2, Phase 3
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Start of enrollment: 2015 Dec 29
Active, not recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

Multidimensional biomarker predicts disease control in response to immunotherapy in recurrent or metastatic head and neck squamous-cell carcinoma.
Kevin C Flanagan, Jon Earls, Ian Schillebeeckx, Jeffrey Hiken, Rachel L Wellinghoff, Natalie A LaFranzo, Zachary S Bradley, Joey Babbitt, William H Westra, Raymond Hsu...> ;Journal of Cancer Research and Clinical Oncology. 2023 Aug 8
384 citations
Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer
Andrew Tutt, Judy Garber, Bella Kaufman, Giuseppe Viale, Debora Fumagalli, Priya Rastogi, Richard D. Gelber, Evandro de Azambuja, Anitra Fielding, Judith Balmaña, Susa...> ;The New England Journal of Medicine. 2021 Jun 3
14 citations
High Pathologic Complete Response in Her2-Positive, Early-Stage Breast Cancer to a Novel Nonanthracycline Neoadjuvant Chemotherapy
Amelia Zelnak, Petros Nikolinakos, Jayanthi Srinivasiah, William Jonas, Andrew Pippas, Yuan Liu, Xiaoxian Li, Mylin A. Torres, Ruth O'Regan> ;Clinical Breast Cancer. 2015 Feb 1
411 citations
Multicenter Phase II and Translational Study of Cetuximab in Metastatic Colorectal Carcinoma Refractory to Irinotecan, Oxaliplatin, and Fluoropyrimidines
Heinz-Josef Lenz, Eric Van Cutsem, Shirin Khambata-Ford, Robert J. Mayer, Philip J. Gold, Philip Stella, B. Mirtsching, Allen Lee Cohn, Andrew William Pippas, Nozar Az...> ;Journal of Clinical Oncology. 2006 Oct 20
Consistent response to treatment with cetuximab monotherapy in patients with metastatic colorectal cancer.
Lenz HJ, Mayer RJ, Mirtsching B, Cohn AL, Pippas A, Windt P, van Cutsem E> ;J. Clin. Oncol.. 2005-06-01
Analysis of EGFR status in metastatic colorectal cancer patients treated with cetuximab monotherapy.
Pippas AW, Lenz HJ, Mayer RJ, Mirtsching B, Cohn AL, Windt P, van Cutsem E> ;J. Clin. Oncol.. 2005-06-01
Activity of cetuximab in patients with colorectal cancer refractory to both irinotecan and oxaliplatin.
Lenz HJ, Mayer RJ, Gold PJ, Mirtsching B, Stella PJ, Cohn AL, Pippas AW, Azarnia N, Needle MN, Van Cutsem E> ;J. Clin. Oncol.. 2004-07-15
15 citations
Controversial topics in breast lymphatic mapping.
James W. Jakub, Charles E. Cox, Andrew Pippas, Mary Gardner, Solange Pendas, Douglas S. Reintgen> ;Seminars in Oncology. 2004 Jun 1
A case report of invasive ductal adenocarcinoma identified in a lymphatic channel: a staging controversy.
James W. Jakub, Francis D. Drake, Andrew Pippas, Mary Gardner, Roberto J. Fraile, Rosemary Giuliano, Solange Pendas, Douglas S. Reintgen> ;Cancer Control. 2003 Sep 1
1 citations
The syndrome of 5-fluorouracil cardiotoxicity: an elusive cardiopathy.
B Weidmann, A Teipel, N Niederle> ;Cancer. 1994 Apr 1
9 citations
THE SYNDROME OF 5-FLUOROURACIL CARDIOTOXICITY : AN ELUSIVE CARDIOPATHY
Norood R. Anderson, Jacob J. Lokich, Cherie Moore> ;Cancer. 1993 Oct 1
91 citations
The syndrome of 5-fluorouracil cardiotoxicity. An elusive cardiopathy.
N C Robben, A W Pippas, J O Moore> ;Cancer. 1993 Jan 15
Join now to see all

Press Mentions

With This Grant Renewal Comes New Initiatives and Grant Aims to Further Expand Cancer Research to a Broader Population and Include Underserved Populations in Cancer Research:July 16th, 2019
Why Precision Medicines for Oncology Demands Precision EngagementMay 24th, 2019

Professional Memberships

American Society of Clinical Oncology - ASCO
Member

Hospital Affiliations

St. Francis HospitalColumbus, Georgia
Piedmont Columbus Regional - Midtown WestColumbus, Georgia
Piedmont Columbus Regional MidtownColumbus, Georgia
Central Alabama Veterans Health Care SystemMontgomery, Alabama
Piedmont Columbus Regional NorthsideColumbus, Georgia